Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies - PubMed (original) (raw)
. 2007 Apr;119(4):1005-11.
doi: 10.1016/j.jaci.2007.01.023. Epub 2007 Mar 2.
Affiliations
- PMID: 17337295
- DOI: 10.1016/j.jaci.2007.01.023
Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies
Stephan von Gunten et al. J Allergy Clin Immunol. 2007 Apr.
Abstract
Background: Human intravenous immunoglobulin (IVIg) preparations are used for the treatment of autoimmune and allergic diseases. Natural autoantibodies are believed to contribute to IVIg-mediated anti-inflammatory effects.
Objective: To address the question of whether IVIg preparations contain anti-sialic acid-binding Ig-like lectin-8 (anti-Siglec-8) autoantibodies.
Methods: The presence of possible anti-Siglec-8 autoantibodies in IVIg preparations was first examined by functional eosinophil death and apoptosis assays. Specificity of IVIg effects was shown by depleting anti-Siglec-8 autoantibodies from IVIg. Binding of purified anti-Siglec-8 autoantibodies to recombinant Siglec-8 was demonstrated by an immunodot assay.
Results: IVIg exerts cytotoxic effects on purified human blood eosinophils. Both potency and efficacy of the IVIg-mediated eosinophil killing effect was enhanced by IL-5, granulocyte/macrophage colony-stimulating factor, IFN-gamma, TNF-alpha, and leptin. Similarly, inflammatory eosinophils obtained from patients suffering from the hypereosinophilic syndrome (HES) demonstrated increased Siglec-8 cytotoxic responses when compared with normal blood eosinophils. Pharmacologic blocking experiments indicated that the IVIg-mediated additional eosinophil death in the presence of cytokines is largely caspase-independent, but it depends on reactive oxygen species. Anti-Siglec-8 autoantibody-depleted IVIg failed to induce caspase-independent eosinophil death.
Conclusion: IVIg preparations contain natural anti-Siglec-8 autoantibodies.
Clinical implications: Anti-Siglec-8 autoantibodies present in IVIg preparations may have therapeutic relevance in autoimmune and allergic diseases, respectively, such as Churg-Strauss syndrome.
Similar articles
- Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
von Gunten S, Simon HU. von Gunten S, et al. Autoimmun Rev. 2008 Jun;7(6):453-6. doi: 10.1016/j.autrev.2008.03.015. Epub 2008 Apr 18. Autoimmun Rev. 2008. PMID: 18558361 Review. - Cell death modulation by intravenous immunoglobulin.
von Gunten S, Simon HU. von Gunten S, et al. J Clin Immunol. 2010 May;30 Suppl 1:S24-30. doi: 10.1007/s10875-010-9411-8. J Clin Immunol. 2010. PMID: 20405180 Review. - Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. von Gunten S, et al. Blood. 2006 Dec 15;108(13):4255-9. doi: 10.1182/blood-2006-05-021568. Epub 2006 Aug 10. Blood. 2006. PMID: 16902148 - Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.
Schaub A, von Gunten S, Vogel M, Wymann S, Rüegsegger M, Stadler BM, Spycher M, Simon HU, Miescher S. Schaub A, et al. Allergy. 2011 Aug;66(8):1030-7. doi: 10.1111/j.1398-9995.2011.02579.x. Epub 2011 Mar 9. Allergy. 2011. PMID: 21385183 - Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury.
Nutku E, Hudson SA, Bochner BS. Nutku E, et al. Biochem Biophys Res Commun. 2005 Oct 28;336(3):918-24. doi: 10.1016/j.bbrc.2005.08.202. Biochem Biophys Res Commun. 2005. PMID: 16157303
Cited by
- Anti-Inflammatory and Immunomodulatory Effect of High-Dose Immunoglobulins in Children: From Approved Indications to Off-Label Use.
Conti F, Moratti M, Leonardi L, Catelli A, Bortolamedi E, Filice E, Fetta A, Fabi M, Facchini E, Cantarini ME, Miniaci A, Cordelli DM, Lanari M, Pession A, Zama D. Conti F, et al. Cells. 2023 Oct 7;12(19):2417. doi: 10.3390/cells12192417. Cells. 2023. PMID: 37830631 Free PMC article. Review. - Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs.
von Gunten S, Schneider C, Imamovic L, Gorochov G. von Gunten S, et al. Front Immunol. 2023 Mar 28;14:1166821. doi: 10.3389/fimmu.2023.1166821. eCollection 2023. Front Immunol. 2023. PMID: 37063852 Free PMC article. Review. - Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.
Segú-Vergés C, Caño S, Calderón-Gómez E, Bartra H, Sardon T, Kaveri S, Terencio J. Segú-Vergés C, et al. Front Immunol. 2022 Sep 30;13:901872. doi: 10.3389/fimmu.2022.901872. eCollection 2022. Front Immunol. 2022. PMID: 36248801 Free PMC article. - Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors.
Liu S, Guo L, Zhang Z, Li M, Zeng X, Wang L, Liu Y, Zhang F. Liu S, et al. Ther Adv Chronic Dis. 2021 Jan 22;12:2040622320987051. doi: 10.1177/2040622320987051. eCollection 2021. Ther Adv Chronic Dis. 2021. PMID: 33613936 Free PMC article. - Discovery, Function, and Therapeutic Targeting of Siglec-8.
Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O'Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, Bochner BS. Youngblood BA, et al. Cells. 2020 Dec 24;10(1):19. doi: 10.3390/cells10010019. Cells. 2020. PMID: 33374255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources